Role Faculty Location Zuckerberg San Francisco General Hospital Category Clinical Publications Dynamic allostery drives autocrine and paracrine TGF-ß signaling. Jin M, Seed RI, Cai G, Shing T, Wang L, Ito S, Cormier A, Wankowicz SA, Jespersen JM, Baron JL, Carey ND, Campbell MG, Yu Z, Tang PK, Cossio P, Wen W, Lou J, Marks J, Nishimura SL, Cheng Y A Three-Monoclonal Antibody Combination Potently Neutralizes BoNT/G Toxin in Mice. Fan Y, Lou J, Tam CC, Wen W, Conrad F, Leal da Silva Alves P, Cheng LW, Garcia-Rodriguez C, Farr-Jones S, Marks JD Multicolor fluorescence activated cell sorting to generate humanized monoclonal antibody binding seven subtypes of BoNT/F. Fan Y, Sun Z, Conrad F, Wen W, Zhao L, Lou J, Zhou Y, Farr-Jones S, Marks JD Structural basis and mechanism of activation of two different families of G proteins by the same GPCR. Alegre KO, Paknejad N, Su M, Lou JS, Huang J, Jordan KD, Eng ET, Meyerson JR, Hite RK, Huang XY A Four-Monoclonal Antibody Combination Potently Neutralizes Multiple Botulinum Neurotoxin Serotypes C and D. Garcia-Rodriguez C, Yan S, Geren IN, Knopp KA, Dong J, Sun Z, Lou J, Conrad F, Wen WH, Farr-Jones S, Smith TJ, Brown JL, Skerry JC, Smith LA, Marks JD A tumor-specific mechanism of Treg enrichment mediated by the integrin αvβ8. Seed RI, Kobayashi K, Ito S, Takasaka N, Cormier A, Jespersen JM, Publicover J, Trilok S, Combes AJ, Chew NW, Chapman J, Krummel MF, Lou J, Marks J, Cheng Y, Baron JL, Nishimura SL Cryo-EM Reveals Integrin-Mediated TGF-β Activation without Release from Latent TGF-β. Campbell MG, Cormier A, Ito S, Seed RI, Bondesson AJ, Lou J, Marks JD, Baron JL, Cheng Y, Nishimura SL The Novel Clostridial Neurotoxin Produced by Strain IBCA10-7060 Is Immunologically Equivalent to BoNT/HA. Fan Y, Barash JR, Conrad F, Lou J, Tam C, Cheng LW, Arnon SS, Marks JD Structural Studies avß8 Integrin by Single Particle Cryo-EM. Melody G. Campbell, Anthony Cormier, Saburo Ito, Shenping Wu, Jianlong Lou, James Marks, Jody L. Baron, Stephen L. Nishimura, Yifan Cheng Botulinum Neurotoxins (BoNTs)-Antibody and Vaccine. Lou J, Marks JD Integrin αvβ8-expressing tumor cells evade host immunity by regulating TGF-β activation in immune cells. Takasaka N, Seed RI, Cormier A, Bondesson AJ, Lou J, Elattma A, Ito S, Yanagisawa H, Hashimoto M, Ma R, Levine MD, Publicover J, Potts R, Jespersen JM, Campbell MG, Conrad F, Marks JD, Cheng Y, Baron JL, Nishimura SL Cryo-EM structure of the αvβ8 integrin reveals a mechanism for stabilizing integrin extension. Cormier A, Campbell MG, Ito S, Wu S, Lou J, Marks J, Baron JL, Nishimura SL, Cheng Y A Three Monoclonal Antibody Combination Potently Neutralizes Multiple Botulinum Neurotoxin Serotype E Subtypes. Garcia-Rodriguez C, Razai A, Geren IN, Lou J, Conrad F, Wen WH, Farr-Jones S, Smith TJ, Brown JL, Skerry JC, Smith LA, Marks JD A Single Tri-Epitopic Antibody Virtually Recapitulates the Potency of a Combination of Three Monoclonal Antibodies in Neutralization of Botulinum Neurotoxin Serotype A. Lou J, Wen W, Conrad F, Meng Q, Dong J, Sun Z, Garcia-Rodriguez C, Farr-Jones S, Cheng LW, Henderson TD, Brown JL, Smith TJ, Smith LA, Cormier A, Marks JD A three monoclonal antibody combination potently neutralizes multiple botulinum neurotoxin serotype F subtypes. Fan Y, Garcia-Rodriguez C, Lou J, Wen W, Conrad F, Zhai W, Smith TJ, Smith LA, Marks JD Yu Ping Feng San reverses cisplatin-induced multi-drug resistance in lung cancer cells via regulating drug transporters and p62/TRAF6 signalling. Lou JS, Yan L, Bi CW, Chan GK, Wu QY, Liu YL, Huang Y, Yao P, Du CY, Dong TT, Tsim KW Inactivation of hypoxia-induced YAP by statins overcomes hypoxic resistance tosorafenib in hepatocellular carcinoma cells. Zhou TY, Zhuang LH, Hu Y, Zhou YL, Lin WK, Wang DD, Wan ZQ, Chang LL, Chen Y, Ying MD, Chen ZB, Ye S, Lou JS, He QJ, Zhu H, Yang B Immunological Characterization and Neutralizing Ability of Monoclonal Antibodies Directed Against Botulinum Neurotoxin Type H. Fan Y, Barash JR, Lou J, Conrad F, Marks JD, Arnon SS Monoclonal Antibodies that Inhibit the Proteolytic Activity of Botulinum Neurotoxin Serotype/B. Fan Y, Dong J, Lou J, Wen W, Conrad F, Geren IN, Garcia-Rodriguez C, Smith TJ, Smith LA, Ho M, Pires-Alves M, Wilson BA, Marks JD Monoclonal Antibodies Targeting the Alpha-Exosite of Botulinum Neurotoxin Serotype/A Inhibit Catalytic Activity. Fan Y, Geren IN, Dong J, Lou J, Wen W, Conrad F, Smith TJ, Smith LA, Ho M, Pires-Alves M, Wilson BA, Marks JD TGF-β-Dependent Dendritic Cell Chemokinesis in Murine Models of Airway Disease. Hashimoto M, Yanagisawa H, Minagawa S, Sen D, Ma R, Murray LA, Tsui P, Lou J, Marks JD, Baron JL, Krummel MF, Nishimura SL Transforming Growth Factor-β and Interleukin-1β Signaling Pathways Converge on the Chemokine CCL20 Promoter. Brand OJ, Somanath S, Moermans C, Yanagisawa H, Hashimoto M, Cambier S, Markovics J, Bondesson AJ, Hill A, Jablons D, Wolters P, Lou J, Marks JD, Baron JL, Nishimura SL 131. Human antibody engineering for prevention and treatment of botulinum neurotoxin (BoNT) intoxication. Jianlong Lou, Consuelo Garcia-Rodriguez, Yongfeng Fan, Jianbo Dong, Weihua Wen, Fraser Conrad, Gabriel Manzanarez, Margarita Sanchez, James D. Marks Development of an ELISA microarray assay for the sensitive and simultaneous detection of ten biodefense toxins. Jenko KL, Zhang Y, Kostenko Y, Fan Y, Garcia-Rodriguez C, Lou J, Marks JD, Varnum SM Selective targeting of TGF-β activation to treat fibroinflammatory airway disease. Minagawa S, Lou J, Seed RI, Cormier A, Wu S, Cheng Y, Murray L, Tsui P, Connor J, Herbst R, Govaerts C, Barker T, Cambier S, Yanagisawa H, Goodsell A, Hashimoto M, Brand OJ, Cheng R, Ma R, McKnelly KJ, Wen W, Hill A, Jablons D, Wolters P, Kitamura H, Araya J, Barczak AJ, Erle DJ, Reichardt LF, Marks JD, Baron JL, Nishimura SL Identification of the synaptic vesicle glycoprotein 2 receptor binding site in botulinum neurotoxin A. Strotmeier J, Mahrhold S, Krez N, Janzen C, Lou J, Marks JD, Binz T, Rummel A Tirapazamine sensitizes hepatocellular carcinoma cells to topoisomerase I inhibitors via cooperative modulation of hypoxia-inducible factor-1α. Cai TY, Liu XW, Zhu H, Cao J, Zhang J, Ding L, Lou JS, He QJ, Yang B RNA aptasensor for rapid detection of natively folded type A botulinum neurotoxin. Janardhanan P, Mello CM, Singh BR, Lou J, Marks JD, Cai S Identification of the SV2 protein receptor-binding site of botulinum neurotoxin type E. Mahrhold S, Strotmeier J, Garcia-Rodriguez C, Lou J, Marks JD, Rummel A, Binz T Comparison of neutralizing abilities of human monoclonal antibodies binding different epitopes on botulinum neurotoxin A. Z. Sun, J. Lou, L. Cheng, T.J. Smith, J. Dong, W. Wen, F. Conrad, C. Garcia, Y. Fan, T. Henderson, J. Brown, J. Skerry, L.A. Smith, T. Harrison, A. D'Andrea, M. Tomic, J.D. Marks Development of an ELISA microarray platform for the sensitive and quantitative detection of botulinum neurotoxins. Y. Zhang, J. Lou, J.D. Marks, K. Jenko, S. Varnum Generation, expression and purification of monoclonal-antibody-specific engineered domains to support development of oligoclonal recombinant antitoxins against BoNT/B and BoNT/E. Q. Meng, C. Garcia, M. Silberg, G. Manzanarez, J. Lou, Y. Fan, F. Conrad, M. Li, J. Freeberg, J. Bettencourt, T. Breece, X. Pan, J. Ma, B. To, C. Obi, M.T. Tomic, J.D. Marks Human monoclonal antibodies binding botulinum neurotoxin types C, D, and mosaic neurotoxins C-D and D-C. C. Garcia, S. Yan, I. Geren, J. Lou, W. Wen, F. Conrad, T.J. Smith, J. Brown, J. Skerry, L.A. Smith, J.D. Marks Monoclonal antibodies against botulinum neurotoxin serotype F. Y. Fan, J. Lou, C. Garcia, W. Zhai, J. Dong, W. Wen, F. Conrad, J. Brown, J. Skerry, T.J. Smith, L.A. Smith, J.D. Marks Quantification of botulinum neurotoxin in intoxicated neurons. K. Bagramyan, D.V. Trinh, J. Lou, Z. Sun, J.D. Marks, M. Kalkum Recombinant monoclonal-antibody-based antitoxins for treatment of types A, B, and E botulism. M. Tomic, C. Garcia, J. Lou, I.N. Geren, Q. Meng, F. Conrad, W. Wen, T.J. Smith, J. Brown, L.A. Smith, A. Wajid, A.C. Dadson, A.H. Horwitz, J. Freeberg, J.D. Marks Simultaneous and sensitive detection of six serotypes of botulinum neurotoxin using enzyme-linked immunosorbent assay-based protein antibody microarrays. Zhang Y, Lou J, Jenko KL, Marks JD, Varnum SM Impact of intrinsic affinity on functional binding and biological activity of EGFR antibodies. Zhou Y, Goenaga AL, Harms BD, Zou H, Lou J, Conrad F, Adams GP, Schoeberl B, Nielsen UB, Marks JD Extraction and inhibition of enzymatic activity of botulinum neurotoxins /B1, /B2, /B3, /B4, and /B5 by a panel of monoclonal anti-BoNT/B antibodies. Kalb SR, Santana WI, Geren IN, Garcia-Rodriguez C, Lou J, Smith TJ, Marks JD, Smith LA, Pirkle JL, Barr JR Affinity maturation to improve human monoclonal antibody neutralization potency and breadth against hepatitis C virus. Wang Y, Keck ZY, Saha A, Xia J, Conrad F, Lou J, Eckart M, Marks JD, Foung SKH Antibodies that bind integrin Alpha-V Beta-8 Stephen Nishimura, Jianlong Lou, Jody Lynn Baron, James D Marks Mouse and human lung fibroblasts regulate dendritic cell trafficking, airway inflammation, and fibrosis through integrin αvβ8-mediated activation of TGF-β. Kitamura H, Cambier S, Somanath S, Barker T, Minagawa S, Markovics J, Goodsell A, Publicover J, Reichardt L, Jablons D, Wolters P, Hill A, Marks JD, Lou J, Pittet JF, Gauldie J, Baron JL, Nishimura SL Response re: 'Neutralizing human monoclonal antibodies binding multiple serotypes of botulinum neurotoxin' by Garcia-Rodriguez et al., PEDS, 2011;24:321-331. Garcia-Rodriguez C, Geren IN, Lou J, Conrad F, Forsyth C, Wen W, Chakraborti S, Zao H, Manzanarez G, Smith TJ, Brown J, Tepp WH, Liu N, Wijesuriya S, Tomic MT, Johnson EA, Smith LA, Marks JD Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors. Rudnick SI, Lou J, Shaller CC, Tang Y, Klein-Szanto AJ, Weiner LM, Marks JD, Adams GP INTEGRIN αVβ8 NEUTRALIZING ANTIBODY Stephen Nishimura, Jianlong Lou, Jody Lynn Baron, James D Marks Neutralizing human monoclonal antibodies binding multiple serotypes of botulinum neurotoxin. Garcia-Rodriguez C, Geren IN, Lou J, Conrad F, Forsyth C, Wen W, Chakraborti S, Zao H, Manzanarez G, Smith TJ, Brown J, Tepp WH, Liu N, Wijesuriya S, Tomic MT, Johnson EA, Smith LA, Marks JD Anti-Botulinum Neurotoxin Antibodies James D. Marks, Jianbo Dong, Jianlong Lou Extraction of BoNT/A, /B, /E, and /F with a single, high affinity monoclonal antibody for detection of botulinum neurotoxin by Endopep-MS. Kalb SR, Garcia-Rodriguez C, Lou J, Baudys J, Smith TJ, Marks JD, Smith LA, Pirkle JL, Barr JR THERAPEUTIC MONOCLONAL ANTIBODIES THAT NEUTRALIZE BOTULINUM NEUROTOXINS James D Marks, Isin Geren, Maria Consuelo Garcia, Jianlong Lou, Ali Razai THERAPEUTIC MONOCLONAL ANTIBODIES THAT NEUTRALIZE BOTULINUM NEUROTOXINS James D Marks, Isin Geren, Jianlong Lou Affinity maturation of human botulinum neurotoxin antibodies by light chain shuffling via yeast mating. Lou J, Geren I, Garcia-Rodriguez C, Forsyth CM, Wen W, Knopp K, Brown J, Smith T, Smith LA, Marks JD Tumor detection by imaging proteolytic activity. Darragh MR, Schneider EL, Lou J, Phojanakong PJ, Farady CJ, Marks JD, Hann BC, Craik CS A single-domain llama antibody potently inhibits the enzymatic activity of botulinum neurotoxin by binding to the non-catalytic alpha-exosite binding region. Dong J, Thompson AA, Fan Y, Lou J, Conrad F, Ho M, Pires-Alves M, Wilson BA, Stevens RC, Marks JD Affinity Maturation by Chain Shuffling and Site Directed Mutagenesis. Jianlong Lou, James D. Marks Antibody Engineering. Roland Kontermann and Stefan Dübel (Eds.) Jianlong Lou and James D Marks Antibody protection against botulinum neurotoxin intoxication in mice. Cheng LW, Stanker LH, Henderson TD, Lou J, Marks JD Rapid multiplexed flow cytometric assay for botulinum neurotoxin detection using an automated fluidic microbead-trapping flow cell for enhanced sensitivity. Ozanich RM, Bruckner-Lea CJ, Warner MG, Miller K, Antolick KC, Marks JD, Lou J, Grate JW Quantum dot immunoassays in renewable surface column and 96-well plate formats for the fluorescence detection of botulinum neurotoxin using high-affinity antibodies. Warner MG, Grate JW, Tyler A, Ozanich RM, Miller KD, Lou J, Marks JD, Bruckner-Lea CJ Extraction and inhibition of enzymatic activity of botulinum neurotoxins/A1, /A2, and /A3 by a panel of monoclonal anti-BoNT/A antibodies. Kalb SR, Lou J, Garcia-Rodriguez C, Geren IN, Smith TJ, Moura H, Marks JD, Smith LA, Pirkle JL, Barr JR Renewable surface fluorescence sandwich immunoassay biosensor for rapid sensitive botulinum toxin detection in an automated fluidic format. Grate JW, Warner MG, Ozanich RM, Miller KD, Colburn HA, Dockendorff B, Antolick KC, Anheier NC, Lind MA, Lou J, Marks JD, Bruckner-Lea CJ Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins Marks James D; Geren Isin N; Garcia Maria Consuelo; Lou Jianlong; Razai Ali. The use of Endopep-MS to detect multiple subtypes of botulinum neurotoxins A, B, E, and F. Suzanne R. Kalb, Theresa J. Smith, Hercules Moura, Karen Hill, Jianlong Lou, Isin N. Geren, Consuelo Garcia-Rodriguez, James D. Marks, Leonard A. Smith, James L. Pirkle, John R. Barr Development of human single-chain antibodies against SARS-associated coronavirus. Leung KM, Feng DX, Lou J, Zhou Y, Fung KP, Waye MM, Tsui SK, Chan PK, Marks JD, Pang SF, Kan YW Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins Marks James D; Amersdorfer Peter; Geren Isin; Lou Jianlong; Razai Ali; Garcia Maria Consuelos Toxicon Marks James, Garcia Consuelo, Isin N. Geren, Lou Jianlong, Charles M. Forsyth, Fraser Conrad, Wen Weihua, Theresa J. Smith, Brown Jennifer, Al-Saleem Fetweh, Ancharski Denise, Lance L. Simpson, William H. Tepp, Eric A. Johnson and Leonard A. Smith Molecular architecture of botulinum neurotoxin E revealed by single particle electron microscopy. Fischer A, Garcia-Rodriguez C, Geren I, Lou J, Marks JD, Nakagawa T, Montal M Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen. Tang Y, Lou J, Alpaugh RK, Robinson MK, Marks JD, Weiner LM THERAPEUTIC MONOCLONAL ANTIBODIES THAT NEUTRALIZE BOTULINUM NEUROTOXINS James D Marks, Peter Amersdorfer, Isin Geren, Jianlong Lou, Ali Razai, Consuelos Maria Garcia Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin. Garcia-Rodriguez C, Levy R, Arndt JW, Forsyth CM, Razai A, Lou J, Geren I, Stevens RC, Marks JD Using phage display to select antibodies recognizing post-translational modifications independently of sequence context. Kehoe JW, Velappan N, Walbolt M, Rasmussen J, King D, Lou J, Knopp K, Pavlik P, Marks JD, Bertozzi CR, Bradbury AR High affinity promotes more effective ADCC by anti-HER2/ neu monoclonal antibodies. Y. Tang, K. Alpaugh, J. Lou, S. Litwin, C. Shaller, G. Adams, J. Marks, L. Weiner Enzyme-amplified protein microarray and a fluidic renewable surface fluorescence immunoassay for botulinum neurotoxin detection using high-affinity recombinant antibodies. Varnum SM, Warner MG, Dockendorff B, Anheier NC, Lou J, Marks JD, Smith LA, Feldhaus MJ, Grate JW, Bruckner-Lea CJ Isolation of scFvs to in vitro produced extracellular domains of EGFR family members. Horak E, Heitner T, Robinson MK, Simmons HH, Garrison J, Russeva M, Furmanova P, Lou J, Zhou Y, Yuan QA, Weiner LM, Adams GP, Marks JD Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization. Smith TJ, Lou J, Geren IN, Forsyth CM, Tsai R, Laporte SL, Tepp WH, Bradshaw M, Johnson EA, Smith LA, Marks JD Molecular evolution of antibody affinity for sensitive detection of botulinum neurotoxin type A. Razai A, Garcia-Rodriguez C, Lou J, Geren IN, Forsyth CM, Robles Y, Tsai R, Smith TJ, Smith LA, Siegel RW, Feldhaus M, Marks JD Yeast mating for combinatorial Fab library generation and surface display. Weaver-Feldhaus JM, Lou J, Coleman JR, Siegel RW, Marks JD, Feldhaus MJ Antibodies in proteomics II: screening, high-throughput characterization and downstream applications. Bradbury A, Velappan N, Verzillo V, Ovecka M, Chasteen L, Sblattero D, Marzari R, Lou J, Siegel R, Pavlik P Antibodies in proteomics I: generating antibodies. Bradbury A, Velappan N, Verzillo V, Ovecka M, Chasteen L, Sblattero D, Marzari R, Lou J, Siegel R, Pavlik P Antibodies in haystacks: how selection strategy influences the outcome of selection from molecular diversity libraries. Lou J, Marzari R, Verzillo V, Ferrero F, Pak D, Sheng M, Yang C, Sblattero D, Bradbury A In vivo recombination as a tool to generate molecular diversity in phage antibody libraries. Sblattero D, Lou J, Marzari R, Bradbury A Applied Biotoxin and Toxicology , Chen Ning Qing, Meng Zhao He( Eds), Lou Jian Long Modern Microbiology and Toxicology Jiao Bing Hua, Xie Zheng Yang( Eds) Lou Jian Long Voltammetric behavior of mammalian tumor cells and bioanalytical applications in cell metabolism. Feng J, Ci YX, Lou JL, Zhang XQ Electromagnetic Biology and Medicine Jun Feng, Ti Yu Gao, Jian Long Lou, Yun Xiang Ci and Zhen Quan Guo Production and characterization of a monoclonal antibody against sterigmatocystin. Lou JL, Guo ZQ, Meng ZH Tumor in China Meng Zhao He, Lou Jian Long, Guo Zhen Quan, Tian He Jing, and Liu Zhao Qian [Production and characterization of sterigmatocystin]. Lou J, Wang Y, Wang D, Meng Z [Determination of sterigmatocystin in cancerous tissues, blood and urine in patients with liver and stomach cancer]. Tian H, Lou J, Du C [Preparation and identification of monoclonal antibody against sterigmatocystin]. Lou J, Guo Z, Meng Z Production and characterization of sterigmatocystin. Lou JL, Meng ZH, Wang DS Journal of Hygiene Research Lou Jianlong, Meng Zhaohe Medical Science Abroad Lou Jian Long, Meng Zhao He Progress in Sterigmatocystin Research Lou Jian Long, Meng Zhao He Chinese Journal of Public Health Lou Jian Long, Zou Kang Nan
